Aardvark Therapeutics (AARD) Competitors $9.77 +0.04 (+0.41%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. URGN, SION, TRVI, IMNM, AKBA, AVXL, QURE, NRIX, PHAR, and AVBPShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Urogen Pharma (URGN), Sionna Therapeutics (SION), Trevi Therapeutics (TRVI), Immunome (IMNM), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), uniQure (QURE), Nurix Therapeutics (NRIX), Pharming Group (PHAR), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Urogen Pharma Sionna Therapeutics Trevi Therapeutics Immunome Akebia Therapeutics Anavex Life Sciences uniQure Nurix Therapeutics Pharming Group ArriVent BioPharma Aardvark Therapeutics (NASDAQ:AARD) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Do analysts prefer AARD or URGN? Aardvark Therapeutics presently has a consensus target price of $32.80, suggesting a potential upside of 235.72%. Urogen Pharma has a consensus target price of $32.00, suggesting a potential upside of 64.61%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor AARD or URGN? In the previous week, Aardvark Therapeutics had 10 more articles in the media than Urogen Pharma. MarketBeat recorded 17 mentions for Aardvark Therapeutics and 7 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.34 beat Aardvark Therapeutics' score of -0.42 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of AARD or URGN? 91.3% of Urogen Pharma shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is AARD or URGN more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -164.44%. Aardvark Therapeutics' return on equity of 0.00% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Urogen Pharma -164.44%-97,487.15%-59.38% Which has higher valuation and earnings, AARD or URGN? Aardvark Therapeutics has higher earnings, but lower revenue than Urogen Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/AUrogen Pharma$90.40M9.95-$126.87M-$3.32-5.86 SummaryAardvark Therapeutics and Urogen Pharma tied by winning 6 of the 12 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.11M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E RatioN/A21.2831.3026.05Price / SalesN/A345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book1.558.129.536.61Net Income-$20.59M-$54.72M$3.26B$265.65M7 Day Performance-9.37%2.62%2.13%2.02%1 Month Performance-31.34%2.68%2.80%-0.31%1 Year PerformanceN/A10.93%30.68%19.06% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$9.77+0.4%$32.80+235.7%N/A$211.11MN/A0.0018News CoverageAnalyst RevisionURGNUrogen Pharma4.5471 of 5 stars$20.07-0.1%$31.43+56.6%+34.5%$928.90M$90.40M-6.05200SIONSionna Therapeutics2.0598 of 5 stars$20.98+0.3%$38.50+83.5%N/A$926.06MN/A0.0035News CoverageTRVITrevi Therapeutics3.0828 of 5 stars$7.39-1.4%$20.38+175.9%+173.6%$899.35MN/A-17.5820Analyst ForecastIMNMImmunome2.0067 of 5 stars$10.31+3.7%$23.14+124.6%-29.4%$894.34M$9.04M-3.3440News CoverageAnalyst ForecastGap UpAKBAAkebia Therapeutics4.0034 of 5 stars$3.29-0.2%$6.75+105.5%+117.0%$873.64M$160.18M-19.38430Analyst RevisionAVXLAnavex Life Sciences3.8871 of 5 stars$10.15+0.4%$44.00+333.4%+55.5%$869.21MN/A-17.7540Analyst ForecastQUREuniQure2.4671 of 5 stars$15.87+0.5%$37.45+136.1%+141.4%$869.20M$27.12M-4.04500Analyst RevisionNRIXNurix Therapeutics2.5909 of 5 stars$10.53-0.3%$28.87+174.3%-56.1%$801.73M$54.55M-4.02300PHARPharming Group2.3819 of 5 stars$11.70+2.8%$30.00+156.5%+72.3%$801.22M$297.20M-89.96280Gap UpAVBPArriVent BioPharma2.4956 of 5 stars$19.65+5.5%$39.14+99.2%-15.8%$796.39MN/A-4.8840 Related Companies and Tools Related Companies URGN Alternatives SION Alternatives TRVI Alternatives IMNM Alternatives AKBA Alternatives AVXL Alternatives QURE Alternatives NRIX Alternatives PHAR Alternatives AVBP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access